More in Health
Multaq Sanctioned for Heart Rhythm Disorders
HealthDay News
Thursday, July 02, 2009
Multaq (dronedarone) tablets have been approved by the U.S. Food and Drug Administration to promote a normal heart rhythm in people with atrial fibrillation or atrial flutter. These conditions cause the heart to beat too quickly and can prevent it from pumping blood correctly.
The drug's label, however, will contain a "black box" warning that the medication could cause deadly reactions in people with recent severe heart failure, the agency said Thursday in a news release.
In clinical testing involving more than 4,000 people, Multaq lowered the rates of cardiac hospitalization or death from any cause by 24 percent, compared to an inactive placebo, the FDA said. The most common side effects were diarrhea, nausea, vomiting, fatigue and weakness.
Multaq is produced by French drug maker Sanofi-Aventis.
More information
The FDA has more about this approval.
Copyright © 2009 ScoutNews, LLC. All rights reserved.
The Daily Reflector
|
Weather
|
Sports
|
Look
|
Business
|
Opinion
|
Classifieds
|
Site Map
Cars
|
Jobs
|
Homes
Copyright 2009 The Daily Reflector All rights reserved. - The Daily Reflector - Our Partners
By using this service, you accept the terms of our
visitor agreement
and
privacy policy. About our ads.
Registered site users, you may edit your profile.
Having trouble? Visit our
help & FAQ
Your comments
Post a Comment
Comments that include profanity, personal attacks or any other inappropriate material are prohibited. By using our site you agree to our ground rules and our terms of use. There could be a delay of up to 5 minutes before your comment appears.